• Earlier this month, Quest Diagnostics announced that its Board of Directors declared a quarterly cash dividend of US$0.86 per share, payable on October 21, 2026 to shareholders of record on October 6, 2026.
• At the same time, Quest’s role powering WHOOP Advanced Labs with access to GRAIL’s Galleri multi-cancer early detection test across nearly 2,000 locations highlights how the company is embedding itself deeper into preventive and consumer-focused diagnostics.
• We’ll now examine how Quest’s expanded role with WHOOP Advanced Labs could influence the existing investment narrative around advanced diagnostics growth.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, you need to be comfortable with a large lab operator that is leaning further into preventive and consumer-focused testing while managing reimbursement and cost pressures. The new US$0.86 dividend and the expanded role with WHOOP Advanced Labs do not materially change the near term focus on driving higher test volumes from advanced diagnostics, or the key risk that pricing pressure and policy changes could weigh on margins.

The most relevant recent announcement here is Quest’s expanded role powering WHOOP Advanced Labs, including access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. This partnership ties directly into one of the core catalysts for the stock: growth in advanced and preventive testing, which could support higher test-per-requisition and help offset industry pricing and reimbursement headwinds over time.

Yet behind the appeal of preventive diagnostics, investors should also be aware of rising exposure to government and exchange based payers...

Quest Diagnostics’ narrative projects $13.3 billion revenue and $1.5 billion earnings by 2029.

Uncover how Quest Diagnostics' forecasts yield a $245.87 fair value, in line with its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$245.87 to US$347.62, showing how far opinions can stretch. Set these against the growth narrative around advanced and preventive testing, and you can see why it pays to compare several viewpoints before deciding how Quest’s future performance might play out.

Explore 2 other fair value estimates on Quest Diagnostics - why the stock might be worth as much as 44% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.